Is Galapagos NV halal to invest in?

As of August 2026, Galapagos NV GLPG.VI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Galapagos NV a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Galapagos NV using these criteria to determine its compliance status.

Can Muslims buy shares of Galapagos NV?

Muslim investors may consider investing in Galapagos NV if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Galapagos NV classified as NOT HALAL?

Musaffa determines the Shariah status of Galapagos NV by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Galapagos NV updated?

The Shariah compliance status of Galapagos NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Galapagos NV become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Galapagos NV?

You can check the latest Shariah compliance status of Galapagos NV on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Galapagos NV GLPG.VI

Last Updated: Aug 06, 12:00 AM·WBAG

GLPG.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Galapagos NV is classified as not halal.

NOT HALAL

Report Source: undefined Quarter Report

Galapagos NV. Stock Analysis GLPG.VI

Austria Health Care Mid Cap

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 452 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.